% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ozair:301321,
      author       = {M. Z. Ozair and B. Halmos and A. D'Aiello and J. Yun and A.
                      R. Filippi and A. Rimner$^*$ and S. H. Lin and C. B. Simone
                      and N. Ohri},
      title        = {{C}hemotherapy-{F}ree {T}reatment with {R}adiotherapy and
                      {I}mmunotherapy for {L}ocally {A}dvanced {N}on-{S}mall
                      {C}ell {L}ung {C}ancer.},
      journal      = {Cancers},
      volume       = {17},
      number       = {9},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2025-00993},
      pages        = {1524},
      year         = {2025},
      abstract     = {Background: Concurrent chemoradiotherapy (CRT) followed by
                      immunotherapy is a standard treatment for locally advanced
                      non-small cell lung cancer (LA-NSCLC), yet many patients are
                      ineligible due to treatment-related toxicity or poor
                      functional status. Chemotherapy-free approaches using
                      radiotherapy (RT) and immunotherapy may offer a safer and
                      equally effective alternative in select patient populations.
                      Methods: A comprehensive literature review was conducted
                      using PubMed, Google Scholar, and relevant conference
                      proceedings focusing on trials between 2000 and 2024.
                      Studies investigating chemotherapy-free regimens combining
                      RT and immunotherapy in LA-NSCLC were analyzed, with
                      emphasis on clinical outcomes, biomarker use, treatment
                      sequencing, radiation dose/fractionation, and safety.
                      Results: Multiple Phase I/II trials reported promising
                      efficacy with one-year progression-free survival (PFS)
                      ranging from $39\%$ to $76\%.$ Toxicity was generally
                      acceptable, though higher-grade adverse events were more
                      frequent in older, frail populations. Trials integrating
                      PD-L1 expression, tumor mutational burden (TMB), and
                      circulating tumor DNA (ctDNA) showed potential for improved
                      patient stratification. Variation in immunotherapy timing
                      (induction, concurrent, or consolidation) and radiation
                      schedules highlight the need for optimization. Conclusions:
                      Chemotherapy-free regimens represent a promising treatment
                      strategy for patients with LA-NSCLC, especially those that
                      are ineligible for standard CRT. Biomarker-driven patient
                      selection and the rational integration of RT and
                      immunotherapy are critical to improving outcomes. Randomized
                      trials are warranted to establish the efficacy and safety of
                      these emerging approaches.},
      subtyp        = {Review Article},
      keywords     = {LA-NSCLC (Other) / chemotherapy-free (Other) /
                      immunotherapy (Other) / radiation therapy (Other)},
      cin          = {FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40361451},
      doi          = {10.3390/cancers17091524},
      url          = {https://inrepo02.dkfz.de/record/301321},
}